Welcome to the Journal
Clinical Investigation (OACLI) (2041-6792) plays significant role in the diagnosis, therapy and cure of diseases apart from new drug development and delivery. The Clinical Investigation Journal offers an Open Access platform to the scholars, amateurs, clinical practitioners and students that are keen in contributing their findings in this field.
Clinical Investigation (OACLI) caters to the clinical drug development and methodology, facilitating rapid publication of research outcome on new drug data from human studies. The journal includes topics like safety and effectiveness of medications, devices, diagnostic products and treatment regimens intended for human use. Also the journal publishes expert analysis of ongoing Phase I–IV trials and perspectives on how to run future trials.
The journal offers thoroughly reviewed original research as research articles, review articles, Clinical Trial Protocols, Clinical Trial Perspectives, Clinical Trial Outcomes, Clinical Trial Reports, Clinical Trial Methodologies, Clinical Trial phase I-IV findings, Commentaries on Clinical trials, case studies, commentaries, Short Communication, and Letters to the Editors in the areas not limited to Regulations and guidelines on drug development and delivery, legal and ethical issues of clinical trials, issues of testing of novel drugs, new medical procedure, new medical devices etc.
Submit your manuscripts online at Editorial Tracking online submission: https://www.scholarscentral.org/submissions/clinical-investigation.html
Contact Editorial Office or send attachment of manuscript at any of the following mail id: [email protected]
Recently Published Articles
Author(s): Rajko FureÃ Â¡, Zlatko HrgoviÃÂ, Sanja JaÃ Â¡ka
OBJECTIVES. We wanted to explore the knowledge and attitudes of pregnant women and women after giving birth to oral health. Likewise, we wanted to determine whether there was any awareness o..
Author(s): Jennifer Stewart
I am pleased to mention that during the year 2019, all issues of volume 9 were published online well within the time and the print issues were also brought out and dispatched within 30 days ..
Review Article p. 166-176
Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ards in COVID-19
Author(s): Fatih M. Uckun, Larn Hwang, Vuong Trieu
Based on the role of TGF- β in the immunopathology of ARDS, we and others have proposed the use of TGF-β inhibitors for the treatment of COVID-19 pneumonia and ARDS. TGF-b targetin..
Review Article p. 177-184
Clinical impact potential of Rejuveinix (RJX) for prevention of fatal acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients
Author(s): Fatih M. Uckun*, Jim Ervin, Kazim Sahin, Joy Powell, Natalie Pizzimenti, Jackie Earabino, Hendrik van Wyk, Mariette van Wyk, Peter Pacult, Taha Koray Sahin, Kristina Cabala
RJX is an Intravenous (IV) formulation of known physiologically compatible compounds that is being developed for more effective supportive therapy of patients with sepsis, including COVID-19..